Rein Therapeutics Inc. (RNTX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-102.3%

-$0.01

vs $0.64 price

Levered DCF

$0.13

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-8.68

Distress zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.59×	-0.66×	-0.62×	-0.35×	-0.36×	-1,766.67×	0×	0×
P/B	1.74×	0.76×	1.42×	0.52×	0.21×	3.04×	0×	0×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-0.52×	-1.01×	-72.52×	31.49×	63×	212.57×	0×	0×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	0.7×	2.38×	4.17×	6.46×	10.69×	4.12×	3.35×	4.05×
Debt / equity	0×	0×	0.01×	0×	0×	0.03×	0.31×	0.27×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-294.8%	-115.6%	-0.2%	-0.1%	-0.1%	-0.2%	0.0%	0.0%
Return on invested capital	-120.3%	-100.1%	-0.0%	-0.1%	-0.1%	-0.2%	0.0%	0.0%
Return on assets	-206.4%	-90.8%	-0.0%	-0.1%	-0.1%	-0.1%	0.0%	0.0%
Free cash flow yield	-65.6%	-54.0%	-203.2%	-258.4%	-254.0%	-55.4%	0.0%	0.0%
Earnings yield	-169.0%	-152.4%	-0.2%	-0.3%	-0.3%	-0.1%	0.0%	0.0%
Enterprise value	$26.3M	$28.4M	-$7.5M	$4.5M	$6M	$30.3M	-$279K	-$5.3M
Net debt / EBITDA	0.06×	0.46×	-166.57×	-36.43×	-36.25×	-46.73×	0×	0×
Cash conversion cycle (days)	-1,451,240	0	0	0	0	0	0	0